1. Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending.;Dusetzina;JAMA Intern Med,2017
2. Payer and policy maker steps to support value-based pricing for drugs.;Bach;JAMA,2015
3. Department of Health and Human Services. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees [Proposed Rule]. https www.federalregister.gov/documents/2019/02/06/2019-01026/fraud-and-abuse-removal-of-safe-harbor-protection-for-rebates-involving-prescription-pharmaceuticals. February 6, 2019. Accessed February 18, 2019.
4. Centers for Medicare and Medicaid Services. Medicare Part D Drug Spending Dashboard & Data. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartD.html. Updated May 23, 2018. Accessed March 3, 2019.
5. Office of Inspector General, US Department of Health and Human Services. High-price drugs are increasing federal payments for Medicare Part D catastrophic coverage. https://oig.hhs.gov/oei/reports/oei-02-16-00270.asp. Published January 2017. Accessed February 18, 2019.